XTX Topco Ltd Buys 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Key Points

• XTX Topco Ltd significantly increased its holdings in Y-mAbs Therapeutics by acquiring an additional 70,686 shares, boosting its stake by 340.4% in the first quarter, resulting in ownership of approximately 0.20% valued at $405,000.
• Y-mAbs Therapeutics has received multiple downgrades from analysts, with Canaccord Genuity and Bank of America reducing their price targets to as low as $3.00, reflecting decreased confidence in the company's performance.
• The stock currently has a market capitalization of $385.33 million and an average price target of $11.16, with analysts generally rating it as a "Hold."

XTX Topco Ltd lifted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 340.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 91,454 shares of the company's stock after buying an additional 70,686 shares during the period. XTX Topco Ltd owned approximately 0.20% of Y-mAbs Therapeutics worth $405,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in YMAB. Bank of America Corp DE lifted its position in Y-mAbs Therapeutics by 59.5% in the fourth quarter. Bank of America Corp DE now owns 127,159 shares of the company's stock worth $996,000 after purchasing an additional 47,439 shares during the period. Exchange Traded Concepts LLC lifted its position in Y-mAbs Therapeutics by 107.9% in the first quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock worth $119,000 after purchasing an additional 13,890 shares during the period. Wells Fargo & Company MN lifted its position in Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Y-mAbs Therapeutics by 17.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock worth $410,000 after purchasing an additional 7,765 shares during the period. Finally, Geode Capital Management LLC lifted its position in Y-mAbs Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after purchasing an additional 8,820 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB traded down $0.01 during mid-day trading on Tuesday, reaching $8.52. The company had a trading volume of 909,356 shares, compared to its average volume of 481,109. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $16.11. The stock has a market capitalization of $385.56 million, a PE ratio of -17.03 and a beta of 0.57. The stock's 50 day moving average is $5.02 and its 200-day moving average is $4.95.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.34%. The business had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. On average, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on YMAB shares. Cantor Fitzgerald set a $8.60 price objective on Y-mAbs Therapeutics and gave the company a "neutral" rating in a research report on Tuesday, August 5th. HC Wainwright reiterated a "neutral" rating and set a $8.60 price objective (down previously from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th. Canaccord Genuity Group downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and cut their target price for the company from $26.00 to $8.60 in a research note on Tuesday, August 5th. Jones Trading reissued a "hold" rating on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Finally, Morgan Stanley set a $8.60 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics has an average rating of "Hold" and a consensus price target of $11.16.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.